Digestery
Longevity supplements › Metformin and Aging › Studies

Population study: followed a group

Study of ovaries in mice and women: metformin use went with less immune activity

McCloskey and colleagues · Clinical cancer research : an official journal of the American Association for Cancer Research · 2020

Original title: Metformin Abrogates Age-Associated Ovarian Fibrosis.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Fibrosis developed in older mouse and human ovaries (n = 27). Metformin use was associated with attenuated CD8+ T-cell infiltration and a reduced CD206+:CD68+ cell ratio.

The study at a glance

Type of study
Population study: followed a group
Who or what was studied
27 people · Aged mice, plus normal human ovaries from women aged 21 to 82 (two groups of 18 and 9)
What was tested
Looked at scarring (fibrosis) in ovaries by age and compared ovaries from metformin users with others
What it measured
Lab tests or markers
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020
Source
PubMed record 31597663. This page is based on the abstract only.

How much this study counts

  • –Shows a link, not a cause: people chose their own habits, and other differences between them may explain the result.
  • ✓Followed people over time, so habits were recorded before the outcome happened.
  • •27 people.
  • –Measured lab tests or markers, which stand in for aging, frailty and death in people without diabetes. A better marker does not always mean better health.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

  4. Population studies

    8

    6 benefit, 2 no difference

    ↑ This study is the ringed dot

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer

Of the other 7 papers on the same step: 5 benefit, 2 no difference. This one found benefit. It agrees with most of them.

  • Open item for a person: Hattersley 2025 (placental ageing in pregnancy) and McCloskey 2020 (ovary tissue markers, metformin users not described) kept relevant as indirect; borderline.

Other papers on the same step

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads differed. The reviewer checked the abstract and kept the first read. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.